Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of XY0206 tablets plus chemotherapy in newly diagnosed FLT3-ITD-mutated acute myeloid leukemia
CTR20234244Phase 2Active
- Sponsor
- Yiling Pharmaceutical
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XY0206 in acute myeloid leukemia (AML), sponsored by Yiling Pharmaceutical. Started Feb 2024; status: active.
02
Drugs
XY0206
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20234244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234244.